| 产品描述: | PD-161570 是一种有效的且具有 ATP 竞争能力的人 FGF-1 受体抑制剂,IC50 为 39.9 nM,Ki 为 42 nM。PD-161570 还抑制 PDGFR,EGFR 和 c-Src 酪氨酸激酶,IC50 值分别为 310 nM,240 nM 和 44 nM。PD-161570 抑制 PDGF 刺激的自磷酸化和 FGF-1 受体磷酸化,IC50 分别为 450 nM 和 622 nM。PD-161570 还是一种骨形态发生蛋白 (BMPs) 和 TGF-β 信号抑制剂。 |
| 靶点: |
FGFR1:39.9 nM (IC50);FGFR1:42 nM (Ki) |
| 体外研究: |
PD-161570 (Compound 6c; 0.1-1 µM; 1-8 days; VSMCs) treatment inhibits PDGF-stimulated vascular smooth muscle cell proliferation in a dose dependent fashion with an IC50 of 0.3 µM on day 8. PD-161570 suppresses constitutive phosphorylation of the FGF-1 receptor in both human ovarian carcinoma cells (A121(p)) and Sf9 insect cells overexpressing the human FGF-1 receptor and blocked the growth of A121(p) cells in culture. PD-161570 can potently inhibit basic fibroblast growth factor (bFGF)-mediated angiogenesis. |
| 参考文献: |
1. Hamby JM, et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem. 1997 Jul 18;40(15):2296-303.
2. Batley BL, et al. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 1998;62(2):143-50.
3. Kyosuke Hino, et al. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva. Stem Cell Reports. 2018 Nov 13;11(5):1106-1119.
4. Wolfe A, et al. Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. J Biomol Screen. 2013 Dec;18(10):1234-45. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.878 ml |
9.389 ml |
18.779 ml |
| 5 mM |
0.376 ml |
1.878 ml |
3.756 ml |
| 10 mM |
0.188 ml |
0.939 ml |
1.878 ml |
| 50 mM |
0.038 ml |
0.188 ml |
0.376 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |